相似文献
1
Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada.
Can Liver J. 2021 Nov 11;4(4):426-429. doi: 10.3138/canlivj-2020-0041. eCollection 2021 Fall.
2
Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
J Int AIDS Soc. 2017 Nov;20(3). doi: 10.1002/jia2.25013.
3
Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
J Hepatol. 2017 Jul;67(1):15-22. doi: 10.1016/j.jhep.2017.01.024. Epub 2017 Feb 9.
4
Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET Medical Information Database Network in Japan.
Ther Innov Regul Sci. 2022 Jul;56(4):625-631. doi: 10.1007/s43441-022-00400-5. Epub 2022 Apr 18.
5
Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions.
J Pharm Pharm Sci. 2018;21(1s):271s-308s. doi: 10.18433/jpps30220.
6
Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment.
Liver Int. 2021 Mar;41(3):464-469. doi: 10.1111/liv.14761. Epub 2020 Dec 23.
7
Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan.
Braz J Biol. 2021 Dec 13;83:e252610. doi: 10.1590/1519-6984.252610. eCollection 2021.
8
A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.
Curr Med Res Opin. 2021 Feb;37(2):245-252. doi: 10.1080/03007995.2020.1857716. Epub 2021 Jan 13.
9
Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
J Viral Hepat. 2017 Aug;24(8):624-630. doi: 10.1111/jvh.12684. Epub 2017 Feb 20.
10
Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570. Epub 2017 Dec 1.
引用本文的文献
1
Universal Pharmacare and Contraceptive Dispensations Among Youth.
JAMA Pediatr. 2025 Aug 18. doi: 10.1001/jamapediatrics.2025.2585.
2
Health service utilization, substance use treatment response, and death in patients with opioid use disorder and comorbid hepatitis C findings from prospective cohort study with administrative database linkage.
J Subst Use Addict Treat. 2024 Dec;167:209524. doi: 10.1016/j.josat.2024.209524. Epub 2024 Sep 26.
3
The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.
PLoS One. 2023 Aug 8;18(8):e0284914. doi: 10.1371/journal.pone.0284914. eCollection 2023.
4
Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.
Can Liver J. 2023 Jul 26;6(2):190-200. doi: 10.3138/canlivj-2022-0040. eCollection 2023 Jul.
5
Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study.
Int J Equity Health. 2023 Jun 6;22(1):112. doi: 10.1186/s12939-023-01924-4.
6
Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study.
Can Commun Dis Rep. 2022 Apr 6;48(4):179-180. doi: 10.14745/ccdr.v48i04a08.
本文引用的文献
1
Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018.
Value Health. 2020 Sep;23(9):1137-1141. doi: 10.1016/j.jval.2020.03.021. Epub 2020 Jul 28.
2
Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Clin Pharmacol Ther. 2021 Mar;109(3):739-745. doi: 10.1002/cpt.2042. Epub 2020 Oct 3.
3
National trends in prescription drug expenditures and projections for 2020.
Am J Health Syst Pharm. 2020 Jul 23;77(15):1213-1230. doi: 10.1093/ajhp/zxaa116.
4
Direct-acting antiviral treatment for hepatitis C.
Lancet. 2019 Apr 6;393(10179):1392-1394. doi: 10.1016/S0140-6736(18)32326-2. Epub 2019 Feb 11.
5
Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015.
Can J Diabetes. 2019 Apr;43(3):179-185.e1. doi: 10.1016/j.jcjd.2018.08.190. Epub 2018 Aug 16.
6
Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.
J Pharm Policy Pract. 2018 Nov 7;11:28. doi: 10.1186/s40545-018-0154-x. eCollection 2018.
7
Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions.
J Pharm Pharm Sci. 2018;21(1s):271s-308s. doi: 10.18433/jpps30220.
8
Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults.
Can Geriatr J. 2018 Sep 30;21(3):269-273. doi: 10.5770/cgj.21.307. eCollection 2018 Sep.
9
Estimated prevalence of Hepatitis C Virus infection in Canada, 2011.
Can Commun Dis Rep. 2014 Dec 18;40(19):429-436. doi: 10.14745/ccdr.v40i19a02.
10
Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program.
CMAJ Open. 2018 Mar 14;6(1):E132-E138. doi: 10.9778/cmajo.20170132.
Zotero 插件